Regression of left ventricular hypertrophy--a meta-analysis

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Left ventricular hypertrophy (LVH) is a significant risk factor for cardiovascular disease.
• Reversing cardiac hypertrophy caused by hypertension is a key goal of antihypertensive treatment.

Purpose of the Study:

• To evaluate the effect of antihypertensive pharmacological therapy on left ventricular mass (LVM) in patients with LVH.
• To compare the efficacy of different first-line antihypertensive drug classes in reducing LVM.

Main Methods:

• A meta-analysis of 2,357 patients receiving antihypertensive therapy.
• Analysis of changes in left ventricular mass (LVM) and mean arterial pressure.
• Adjusted analysis (ANCOVA) to compare the effects of ACE-inhibitors, beta-blockers, calcium antagonists, and diuretics on LVM.

Main Results:

• Antihypertensive therapy reduced overall left ventricular mass (LVM) by 11.9% and mean arterial pressure by 14.9%.
• Absolute LVM reductions varied by drug class: ACE-inhibitors (44.7g), calcium antagonists (26.9g), beta-blockers (22.8g), and diuretics (21.4g).
• ACE-inhibitors, beta-blockers, and calcium antagonists primarily reduced LVM by decreasing wall thickness, while diuretics acted mainly on the inner diameter.

Conclusions:

• Effective antihypertensive treatment demonstrably reduces left ventricular mass (LVM).
• ACE-inhibitors exhibit the most significant impact on reducing LVM through wall hypertrophy reduction.
• The long-term prognostic implications of these LVM reduction mechanisms require further investigation.